Cambridge Cognition Returns to Growth as New Orders Surge and Market Reach Widens

The latest update is out from Cambridge Cognition Holdings ( (GB:COG) ).

Cambridge Cognition reported a strong rebound in 2025 new business, with sales orders surging 73% to £12.8m and the year-end order book up 21% to £16.5m, even as revenues slipped 10% to about £9.4m due to a weak opening order book and the long-cycle nature of clinical contracts. Tight cost control limited the adjusted EBITDA loss to £0.5m, operating cash flow turned positive, net cash moved to roughly £0.3m after reducing borrowings, and the group expanded from its core clinical and academic markets into professional healthcare and consumer health, underpinning management’s expectation of revenue growth in 2026 and signalling a stronger platform for future earnings and cash generation.

Spark’s Take on COG Stock

According to Spark, TipRanks’ AI Analyst, COG is a Neutral.

Overall score reflects weak financial performance driven by declining revenue, ongoing losses, and negative operating/free cash flow, partially offset by improved equity on the balance sheet. Technicals are mixed (short-term strength but longer-term downtrend and overbought RSI), while valuation is constrained by loss-making results and no stated dividend yield.

To see Spark’s full report on COG stock, click here.

More about Cambridge Cognition Holdings

Cambridge Cognition Holdings is a neuroscience technology company specialising in digital cognitive assessments that support scientific discovery, accelerate drug development and improve patient care. Its scalable, data-driven platforms target four sectors worldwide: clinical pharmaceutical studies, academic research into central nervous system disorders, physician-led healthcare diagnostics, and consumer health and wellness cognitive monitoring.

Average Trading Volume: 34,790

Technical Sentiment Signal: Hold

Current Market Cap: £18.16M

For a thorough assessment of COG stock, go to TipRanks’ Stock Analysis page.